What happened
TCGX Acquisition Corp. (NASDAQ: TCGX) said it expects a TriGemX Bio, Inc. deal to close with about $246 million in gross proceeds.
If TCGX public shareholders do not redeem, the combined company is expected to have a post-transaction equity value of about $600 million at closing.
Key numbers
| Metric | Latest | Change | Source |
|---|---|---|---|
| Post-transaction equity value at closing | $600 million | SEC 8-K | |
| Expected gross proceeds | $246 million | SEC 8-K | |
| Cash as of October 1, 2026 | $111 million | SEC Exhibit 99.2 | |
| Greater exposure at 2 hours versus previous DFC formulation | 2.3x | SEC Exhibit 99.2 |
Read more: TCGX Acquisition (TCGX) stock analysis and investment case
Why it matters
The expected gross proceeds are about 41% of the combined company's expected equity value. That gives investors a quick read on the deal's size.
That matters because the presentation says TriGemX is a clinical-stage biopharmaceutical company with no product revenues, has incurred operating losses since inception and expects more financing.
TriGemX says it had about $111 million in cash as of October 1, 2026, and that cash was expected to fund operations into Q3 2027.
TriGemX also says elismetrep is in Phase 3 for acute treatment of migraine, with readout expected in mid-2027 and early 2028 and an NDA targeted for mid-2028.
The presentation says Phase 2b showed placebo-adjusted +10.5% pain freedom, +14.0% MBS freedom and +16.4% pain relief at 2 hours for the 20 mg dose.
It also says favorable safety data came from 13 clinical trials with about 1,000 subjects exposed to elismetrep.
The presentation says certain U.S. patents run into the mid-2040s.
It also says the combined company will have broad discretion in using net proceeds from the private placement.
The key caveat is that both the valuation and the proceeds assume no redemptions, the proceeds are before transaction costs and the filing says there can be no assurance the transaction closes.
Stock perps: every US stock that trades as a perpetual future, by leverage, live
What's next
Next, TCGX and TriGemX plan to file the registration statement that will include the proxy statement and prospectus for the shareholder meeting.
If that filing moves ahead and shareholders approve the deal, it would support the path to closing.
Heavy redemptions or a failed vote would weaken the financing base and the deal's route to closing.
More from OptimistFi
- TCGX stock: the TCGX Acquisition thesis, its status and the next test to watch
- Stock research on every company OptimistFi covers
From OptimistFi Perps
- Open interest live: crypto and stock perps by exchange
- All perp markets: price, open interest and funding by venue
- Futures calculator: liquidation price, PnL and fees by exchange
- Perp funding rates live: what longs and shorts pay on every venue
- Stock perps vs tokenized stocks: how US shares trade around the clock
- Weekend market prices: US stock indexes, gold and oil now
Sources
- SEC 8-K — Business combination valuation and expected gross proceeds.
- SEC Exhibit 99.2 — Presentation with transaction context, clinical program details and cash balance.
Read the full OptimistFi thesis on TCGX Acquisition Corp.: https://optimistfi.com/stocks/TCGX
See what would break the TCGX Acquisition Corp. thesis and track it live on the OptimistFi Thesis-Break Engine.
Browse every company OptimistFi covers at optimistfi.com/stocks, or read the latest evidence-first research.
The full TCGX Acquisition Corp. investment case, its status and the next test to watch live on the TCGX Acquisition Corp. thesis page.
Originally published on OptimistFi, evidence-first equity research. More at optimistfi.com.
